Results 141 to 150 of about 21,018 (198)

Combination of FTO and BTK inhibitors synergistically suppresses the malignancy of breast cancer cells. [PDF]

Int J Biol Sci
Saad AAA, Ge L, Wang H, Xia Y, Li J, Qiao S, Yi C, Wang X, Wang Z, Zhou D, Wang H.   +10 more
europepmc   +1 more source

Dynamic Interplay of miR-155-5p Transfer in the Mechanisms Underlying Ibrutinib Resistance in DLBCL through Extracellular Vesicles [PDF]

Bon Park, Myung Eun Choi, Kyung Ju Ryu, Chaehwa Park, Sang Eun Yoon, Won Seog Kim, Jung Yong Hong, Seok Jin Kim   +7 more
openalex   +1 more source

Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study [PDF]

Wenhua Wang, Bingyi Wang, Yifei Sun, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Zheng Song, Wei Li, Lanfang Li, Xianhuo Wang, Huilai Zhang, Huilai Zhang   +11 more
openalex   +1 more source

Influence of CYP2D6, CYP3A, and ABCG2 Genetic Polymorphisms on Ibrutinib Disposition in Chinese Healthy Subjects. [PDF]

Pharmaceuticals (Basel)
Fu K, Wang Y, Duan L, Zhang Z, Qian J, Chen X, Liang Y, Lu C, Zhao D.   +8 more
europepmc   +1 more source

Chihara D, Steiner RE, Nair R, et al. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Adv. 2025;9(7):1485-1491. [PDF]

Blood Adv
europepmc   +1 more source

Ibrutinib and PD-1 blockade potentiate mesothelin-targeting CAR-T cell therapy in preclinical models of pancreatic cancer. [PDF]

Clin Cancer Res
Armstrong A, van der Plancke G, Nishiguchi S, Salas-Benito D, Bouffard AA, Goncalves S, Merce AT, Kelly C, Birocchi F, Park S, Leick MB, Horick N, Berger TR, Maus MV, Escobar G.   +14 more
europepmc   +1 more source

Successful Treatment of Monoclonal Immunotactoid Glomerulopathy Associated with Chronic Lymphocytic Leukemia Using Ibrutinib

Ayano Saito, Yoshihiro Kameoka, Kumi Ubukawa, Hiroshi Ohtani, Fumito Abe, Masaya Saito, Mako Hashimoto, Tatsuro Kanazawa, Atsushi Komatsuda, Naoto Takahashi   +9 more
openalex   +2 more sources

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

, 2014
Holbrook E. Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E.M. Herman, Jonathan P. Butchar, Carolyn Cheney, Xiaoli Zhang, Joseph J. Buggy, Natarajan Muthusamy, Ronald Levy, Amy J. Johnson, John C. Byrd   +11 more
openalex   +2 more sources

Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs. [PDF]

J Comp Eff Res
Fitzgerald L, Ghosh S, Bokun A, Lax A, Mu F, Wu E, Lin Y, Shi L, Qureshi ZP, Graf SA.   +9 more
europepmc   +1 more source

Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia. [PDF]

Hematol Transfus Cell Ther
Nascimento AD, Curado DDSP, Montezuma T, Barbosa WB, Machado-Rugolo J, Fachi MM.   +5 more
europepmc   +1 more source